Fundraising FoxSocial Impact Capital — 2017 Investments
1 investments dated 2017 · listed companies and verified rows first · show all
Curemarkcuremark.comin𝕏Mar 2017SEC filingmedium confidence
Curemark is a clinical-stage biopharmaceutical company developing therapies for neuro-developmental and neurodegenerative disorders.
BiotechHealthtechRye Brook, US
Joan Fallon(Executive Officer, Director)inMatthew Heil(Executive Officer)in
BoardLeigh Morgan(Director)Kimbell Duncan(Director)
Board seatJustin Stebbing· per SEC Form D · $150M raise · filed Mar 2017
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.